# Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS

> **NCT05947747** · PHASE2 · UNKNOWN · sponsor: **Nano24med** · enrollment: 90 (estimated)

## Conditions studied

- ARDS

## Interventions

- **DRUG:** EXO-CD24
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05947747
- **Lead sponsor:** Nano24med
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-04
- **Primary completion:** 2025-12-20
- **Final completion:** 2025-12-20
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947747, "Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05947747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*